Ultromics

Name: Ultromics
Brand: Ultromics

Ultromics is transforming the detection of heart failure using artificial intelligence for echocardiography.

Est 2017|28 Ref Customers

LinkedIn 10K|Web traffic 22K|FTEs 85|HQ Oxford, England, GB

01Competitive Landscape

| Aspect | Ultromics (EchoGo platform) | Us2.ai | DiA Imaging Analysis | |--------|-----------------------------|--------|----------------------| | Starting Price | Not publicly listed; vendor materials suggest enterprise contracting and possible per-analysis pricing; reimbursement context is highlighted | Not publicly listed in sources reviewed | Not publicly listed in sources reviewed | | Primary Use Case | Screening-focused disease-detection modules (HFpEF and cardiac amyloidosis) plus automated echo measurements integrated into DICOM workflows | Automated cardiac phenotyping and guideline-aligned reporting for echo studies; regulatory listing noted in vendor materials | Echo workflow automation and ultrasound AI measurement tools | | Key Strength | Regulatory clearances for specific disease-detection modules and vendor emphasis on integration into clinical workflow and reimbursement pathways | Broad echo analysis and phenotyping capability; regulatory listing indicates clearance in certain products | Established presence in ultrasound AI measurement automation | | Key Weakness | Limited publicly accessible, independent end-user reviews; pricing transparency is limited; detailed enterprise security documentation not publicly available | Similar transparency issues common to medtech AI vendors; public pricing/review density limited | Disease-specific screening differentiation versus Ultromics unclear from publicly available materials | - Narrative analysis - Product differentiation - The vendor emphasizes regulated, disease-specific screening modules for HFpEF and cardiac amyloidosis and automated measurement outputs integrated into existing imaging workflows. - Where alternatives may excel - Vendors focused on broad echo phenotyping and guideline-driven reporting may offer a wider range of study interpretation features compared with a module-focused approach. - OEM vendors may provide tighter integration with ultrasound platforms and bundled procurement options that can reduce integration complexity. - Pricing/value comparison - The vendor highlights reimbursement pathways and coding context as part of its value narrative; purchasers should separate reimbursement policy from vendor pricing when estimating ROI. - Market share and adoption trends - The vendor indicates presence in hospital deployments but does not publish a comprehensive customer list in the sources reviewed; independent market-share data was not identified.

01Competitive Landscape

Aspect	Ultromics (EchoGo platform)	Us2.ai	DiA Imaging Analysis
Starting Price	Not publicly listed; vendor materials suggest enterprise contracting and possible per-analysis pricing; reimbursement context is highlighted	Not publicly listed in sources reviewed	Not publicly listed in sources reviewed
Primary Use Case	Screening-focused disease-detection modules (HFpEF and cardiac amyloidosis) plus automated echo measurements integrated into DICOM workflows	Automated cardiac phenotyping and guideline-aligned reporting for echo studies; regulatory listing noted in vendor materials	Echo workflow automation and ultrasound AI measurement tools
Key Strength	Regulatory clearances for specific disease-detection modules and vendor emphasis on integration into clinical workflow and reimbursement pathways	Broad echo analysis and phenotyping capability; regulatory listing indicates clearance in certain products	Established presence in ultrasound AI measurement automation
Key Weakness	Limited publicly accessible, independent end-user reviews; pricing transparency is limited; detailed enterprise security documentation not publicly available	Similar transparency issues common to medtech AI vendors; public pricing/review density limited	Disease-specific screening differentiation versus Ultromics unclear from publicly available materials

Narrative analysis
- Product differentiation
  - The vendor emphasizes regulated, disease-specific screening modules for HFpEF and cardiac amyloidosis and automated measurement outputs integrated into existing imaging workflows.
- Where alternatives may excel
  - Vendors focused on broad echo phenotyping and guideline-driven reporting may offer a wider range of study interpretation features compared with a module-focused approach.
  - OEM vendors may provide tighter integration with ultrasound platforms and bundled procurement options that can reduce integration complexity.
- Pricing/value comparison
  - The vendor highlights reimbursement pathways and coding context as part of its value narrative; purchasers should separate reimbursement policy from vendor pricing when estimating ROI.
- Market share and adoption trends
  - The vendor indicates presence in hospital deployments but does not publish a comprehensive customer list in the sources reviewed; independent market-share data was not identified.

Aspect

Ultromics (EchoGo platform)

Us2.ai

DiA Imaging Analysis

Starting Price

Not publicly listed; vendor materials suggest enterprise contracting and possible per-analysis pricing; reimbursement context is highlighted

Not publicly listed in sources reviewed

Primary Use Case

Screening-focused disease-detection modules (HFpEF and cardiac amyloidosis) plus automated echo measurements integrated into DICOM workflows

Automated cardiac phenotyping and guideline-aligned reporting for echo studies; regulatory listing noted in vendor materials

Echo workflow automation and ultrasound AI measurement tools

Key Strength

Regulatory clearances for specific disease-detection modules and vendor emphasis on integration into clinical workflow and reimbursement pathways

Broad echo analysis and phenotyping capability; regulatory listing indicates clearance in certain products

Established presence in ultrasound AI measurement automation

Key Weakness

Limited publicly accessible, independent end-user reviews; pricing transparency is limited; detailed enterprise security documentation not publicly available

Similar transparency issues common to medtech AI vendors; public pricing/review density limited

Disease-specific screening differentiation versus Ultromics unclear from publicly available materials

Ultromics

01Competitive Landscape

02Market Map

01Competitive Landscape

02Market Map